Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir Prophylaxis for CMV in GVHD Patients
NCT05969743Phase 2Unknown
- Sponsor
- Rabin Medical Center
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of letermovir in cytomegalovirus infection (CMV), sponsored by Rabin Medical Center. Primary endpoint: Incidence of CMV infection at 14 weeks. Status: unknown.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05969743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969743.